Genetic changes observed in prostate cancer

Central European Journal of Urology

Volumn 62, Issue 1, 2009, Pages 4-8

  Dominska, Kamila ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hereditary prostate cancer; Prostate; Prostate cancer

Indexed keywords

EID: 79960664010     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2009.01.art1     Document Type: Review

References (52)

1. Schaid DJ: The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 1; 13; 103-121.
2. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI: Pathological and molecular aspects of prostate cancer. Lancet 2003; 15; 361; 955-964.
3. Nwosu V, Carpten J, Trent JM, Sheridan R: Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001; 1; 10; 2313-2318.
4. Dong JT: Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97; 433-447.
5. Smith JR, Freije D, Carpten JD et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 22; 274; 1371-1374.
6. Nam RK, Zhang WW, Loblaw DA et al: A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Cancer Prostatic Dis 2008; 11; 241-246.
7. Xu J: Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 2000; 66; 945-957.
8. Rennert H, Zeigler-Johnson C, Mittal RD e al: Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Urology 2008; 72; 456-460.
9. Goode EL, Stanford JL, Chakrabarti L et al: Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol 2000; 18; 251-275.
10. Zhou A, Molinaro RJ, Malathi K, Silverman RH: Mapping of the human RNASEL promoter and expression in cancer and normal cells. J Interferon Cytokine Res 2005; 25; 595-603.
11. Li G, Xiang Y, Sabapathy K, Silverman RH: An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 2004; 279; 1123-1131.
12. Rokman A, Ikonen T, Seppala EH et al: Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70; 1299-1304.
13. Wiklund F, Jonsson BA, Brookes AJ et al: Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10; 7150-7156.
14. Casey G, Neville PJ, Plummer SJ et al: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32; 581-583.
15. Xiang Y, Wang Z, Murakami J et al: Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res 2003; 63; 6795-6801.
16. Nakazato H, Suzuki K, Matsui H et al: Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 2003; 89; 691-696.
17. Daugherty SE, Hayes RB, Yeager M et al: RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate. 2007; 67; 849-854.
18. Rennert H, Bercovich D, Hubert A et al: A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71; 981-984.
19. Orr-Urtreger A, Bar-Shira A, Bercovich D et al: RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15; 474-479.
20. Datta MW, Hernandez AM, Schlicht MJ et al: Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol Cancer 2006; 1; 5-9.
21. Cancel-Tassin G, Latil A, Valeri A et al: PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 2001; 9; 135-142.
22. Tavtigian SV, Simard J, Teng DH et al: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27; 172-180.
23. Rebbeck TR, Walker AH, Zeigler-Johnson C et al: Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000; 67; 1014-1019.
24. Suarez BK, Gerhard DS, Lin J et al: Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001; 61; 4982-4984.
25. Yokomizo A, Koga H, Kinukawa N et al: HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate 2004; 61; 248-252.
26. Minagawa A, Takaku H, Takagi M, Nashimoto M: The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product. Cancer Lett 2005; 26; 222; 211-215.
27. Berry R, Schroeder JJ, French AJ et al: Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000; 67; 82-91.
28. Bar-Shira A, Pinthus JH, Rozovsky U et al: Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res 2002; 62; 6803-6807.
29. Schaid DJ, Chang BL: Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13. Prostate. 2005; 63; 276-290.
30. Schleutker J, Matikainen M, Smith J et al: A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with lateonset disease. Clin Cancer Res 2000; 6; 4810-4815.
31. Kouprina N, Pavlicek A, Noskov VN et al: Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 2005; 15; 1477-1486.
32. Alers JC, Krijtenburg PJ, Vis AN et al: Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 2001; 158; 399-406.
33. Abate-Shen C, Shen MM, Gelmann E: Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008; 76; 717-727.
34. Bowen C, Bubendorf L, Voeller HJ et al: Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60; 6111-6115.
35. Sun J, Turner A, Xu J, Grönberg H, Isaacs W: Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007; 25; 250-259.
36. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB: The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172; S6-11.
37. Xu J, Zheng SL, Komiya A et al: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32; 321-325.
38. Hsing AW, Sakoda LC, Chen J et al: MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Carcinogenesis 2007; 28; 2530-2536.
39. Wang L, McDonnell SK, Cunningham JM et al: No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet 2003; 35; 128-129.
40. Cybulski C, Wokołorczyk D, Jakubowska A et al: DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 2007; 79; 44-49.
41. Srivastava M, Bubendorf L, Srikantan V et al: ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci U S A 2001; 98; 4575-4580.
42. Bertram J, Peacock JW, Fazli L et al: Loss of PTEN is associated with progression to androgen independence. Prostate 2006; 66; 895-902.
43. Chen C, Bhalala HV, Vessella RL, Dong JT: KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003; 55; 81-88.
44. Hyytinen ER, Frierson HF Jr, Boyd JC et al: Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999; 25; 108-114.
45. Edwards SM, Kote-Jarai Z, Meitz J et al: Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72; 1-12.
46. Willems AJ, Dawson SJ, Samaratunga H et al: Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 2008; 14; 2953-2961.
47. Narod SA, Neuhausen S, Vichodez G et al: Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99; 371-374.
48. Matsuyama H, Pan Y, Yoshihiro S, Kudren D et al: Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate 2003; 54; 103-111.
49. Sun X, Frierson HF, Chen C et al: Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 2005; 37; 407-412.
50. Jaeger EB, Samant RS, Rinker-Schaeffer CW: Metastasis suppression in prostate cancer. Cancer Metastasis Rev 2001; 20; 279-286.
51. Alers JC, Rochat J, Krijtenburg PJ et al: Identification of genetic markers for prostatic cancer progression. Lab Invest 2000; 80; 931-942.
52. Ellinger J, Bastian PJ, Jurgan T et al: CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008; 71; 161-167.